Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciencesnews2025-05-29T23:30:43+00:00May 29th, 2025|Endpoints News|
TCG’s R&D venture team makes a T cell engager deal with Shanghai biotechnews2025-05-27T10:00:57+00:00May 27th, 2025|Endpoints News|
Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBionews2025-05-20T07:24:02+00:00May 20th, 2025|Endpoints News|
In the Future, China Will Be Dominant. The U.S. Will Be Irrelevant.news2025-05-19T06:19:57+00:00May 19th, 2025|The New York Times|
Merck KGaA Q1 earnings: Tariff surcharge for US customers will continuenews2025-05-15T11:03:52+00:00May 15th, 2025|Endpoints News|
Hengrui, one of China’s leading biotechs, anticipates $1.2B in proposed Hong Kong listingnews2025-05-15T08:52:29+00:00May 15th, 2025|Endpoints News|
Chinese Imports to US Hit 20-Year Low as Tariffs Sink Innews2025-05-06T21:34:58+00:00May 6th, 2025|The New York Times|
Early in vivo CAR-T human data emerge from biotech trials in Chinanews2025-05-05T10:00:52+00:00May 5th, 2025|Endpoints News|
Pfizer’s Bourla projects confidence that tariffs will focus on US adversariesnews2025-04-29T19:04:58+00:00April 29th, 2025|Endpoints News|
AstraZeneca, Novartis execute ‘US for US’ strategy as pharma tariffs nearnews2025-04-29T11:22:54+00:00April 29th, 2025|Endpoints News|
